The week in health tech, explained in plain English.Get the free newsletter →
October 24, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Health IT

Sophia Genetics, MSK Plan NYC Precision Oncology Hub

By Healthcare Technology News ·

Sophia Genetics and Memorial Sloan Kettering Cancer Center have signed a memorandum of understanding to create a joint venture that would establish a precision medicine hub in New York City, according to MobiHealthNews. The plan pairs MSK's deep clinical and genomic expertise with Sophia Genetics' SOPHiA DDM platform, which uses artificial intelligence to analyze genomic and multimodal data and help match cancer patients to targeted therapies.

The move reflects a broader industry push to turn vast troves of genomic and clinical data into faster, more accurate cancer care. Precision oncology depends on interpreting complex tumor profiles at scale, and partnerships between academic cancer centers and data-analytics companies are becoming a common route to do that work without building everything in-house.

An MOU is a preliminary step, not a finalized deal, so terms, funding, and timing remain to be settled. If completed, the hub would give both partners a platform to commercialize data-driven diagnostics and expand access to advanced genomic testing.

Sources

More in Health IT

Health IT

Epic Opens Its Platform Wider to AI and Outside Developers

Epic used its Open@Epic developer conference to open its platform wider to outside AI and apps while reminding developers that the resulting traffic runs on hospitals' infrastructure.

Why it matters: As the dominant EHR vendor, Epic's decision to open its platform shapes how and where clinical AI gets deployed across most U.S. hospitals.

Health IT

After AI Go-Live, Who Owns Monitoring? Often No One

Health systems scrutinize AI before go-live, but post-deployment monitoring responsibilities often remain undefined, leaving no clear owner when models drift.

Why it matters: Unmonitored AI models can quietly degrade in clinical settings, putting patient safety at risk when no one is accountable for watching performance after launch.